Clinical Trial Update: Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma [Phase 1]

View source ↗

Summary

Phase 1 trial of super-selective intra-arterial bevacizumab (Avastin) for vestibular schwannoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vestibular Schwannoma

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Northwell Health | Conditions: Vestibular Schwannoma | Phase 1 | Status: SUSPENDED